Schickel J, Pamminger T, Ehrsam A, Münch S, Huang X, Klopstock T, Kurlemann G, Hemmerich P, Dubiel W, Deufel T, Beetz C
Institut für Klinische Chemie und Laboratoriumsdiagnostik, Universitätsklinikum, Jena, Germany.
Eur J Neurol. 2007 Dec;14(12):1322-8. doi: 10.1111/j.1468-1331.2007.01971.x. Epub 2007 Oct 3.
Hereditary spastic paraplegia (HSP) is a neurodegenerative disorder selectively affecting axons of spinal cord motoneurons. Classical mutations in the most frequent HSP gene SPAST (spastin protein) act through haploinsufficiency by abolishing the activity of a C-terminal ATPase domain or by interfering with expression from the affected allele. N-terminal missense variants have been suggested to represent rare polymorphisms, to cause unusually mild phenotypes, and to aggravate the effect of a classical mutation. We confirm these associations for p.S44L but do not detect two other variants (p.E43Q; p.P45Q) in HSP patients and controls. We show that neither of several disease mechanisms associated with classical SPAST mutations applies to the N-terminal variants. Instead, all three alterations enhance the stability of one of two alternative spastin isoforms. Their phenotypic effect may thus not be mediated by haploinsufficiency but by increasing isoform competition for interacting proteins, substrates or oligomerization partners.
遗传性痉挛性截瘫(HSP)是一种神经退行性疾病,选择性地影响脊髓运动神经元的轴突。最常见的HSP基因SPAST(痉挛蛋白)中的经典突变通过单倍剂量不足起作用,即通过消除C末端ATP酶结构域的活性或干扰受影响等位基因的表达。N末端错义变体被认为代表罕见的多态性,导致异常轻微的表型,并加重经典突变的影响。我们证实了p.S44L的这些关联,但在HSP患者和对照中未检测到其他两个变体(p.E43Q;p.P45Q)。我们表明,与经典SPAST突变相关的几种疾病机制均不适用于N末端变体。相反,所有这三种改变都增强了两种替代痉挛蛋白异构体之一的稳定性。因此,它们的表型效应可能不是由单倍剂量不足介导的,而是通过增加异构体对相互作用蛋白、底物或寡聚化伙伴的竞争来介导的。